



Subject: Influenza Vaccination*

Effective Date: October 2, 2003

Department(s): Utilization Management

Policy: Influenza vaccine, either injectable or intranasal, is reimbursable under Plans administered by QualCare, Inc.

Objective: To assure proper and consistent reimbursement and to assure coverage of a medically necessary service.

Procedure:

- Injectable influenza vaccine (CPT Codes 90654, 90655, 90656, 90657, 90658, 90660, 90661, 90662, 90673, 90685, 90686, 90687, 90688; HCPCS codes Q2034, Q2035, Q2036, Q2037, Q2038, and Q2039) will be authorized for any member, according to the Plan's adult and pediatric wellness policies, when the member's physician recommends it.
- Intranasal influenza vaccine (CPT Code 90660, 90672) will be authorized for members from age 2 years through age 49 years, according to the Plan's adult and pediatric wellness policies, when the member's physician recommends it.

References

Caspar H, Heikkinen T, Belshe RB, Ambrose CS. A Systematic Review of the Efficacy of Live Attenuated Influenza Vaccine Upon Revaccination of Children. *Hum Vaccin Immunother*. 2016 Jan 11:0. [Epub ahead of print]

American Academy of Pediatrics Recommendations for Prevention and Control of Influenza in Children, 2015-16. Committee on Infectious Diseases. Accessed at pediatrics.aappublications.org

Prevention and Control of Influenza with Vaccines: Recommendations of the ACIP-U.S., 2015-16 Influenza Season. *MMWR* 2015;63(30):817-25(Aug)

Centers for Disease Control and Prevention (CDC). ACIP Recommendations. Available at: <http://www.cdc.gov/vaccines/pubs/ACIP-list.htm>. Accessed on August 22, 2013.

Kieninger D, Sheldon E, Lin WY, Yu CJ, et al. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults ≥ 18 years. *BMC Infect Dis*. 2013;13(1):343(Jul)[Epub ahead of print]

LangleyJM, Carmona Martinez A, ChatterjeeA, Halperin SA, et al. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children. *J Infect Dis*. 2013;208(4):544-53(Aug)

U.S. Food and Drug Administration. FDA Approves Vaccine for 2009 – 2010 Seasonal Influenza. FDA News Release. July 20, 2009. Available at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm172772.htm. Accessed 07/22/09

U.S. Food and Drug Administration. Nasal Influenza Vaccine Approved for Younger Children. Consumer Update posted 09/26/07

---Influenza Vaccine 2005-2006. *Medical Letter* 2005;47(1220):85-87 (Oct 24)

Centers for Disease Control and Prevention. Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2005;54(RR-8) (Jul 29)

Centers for Disease Control and Prevention. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR* 2003;52(RR-13) (Sep 26)

Flumist: An intranasal live influenza vaccine. *Medical Letter* 2003;45(1163):65-66 (Aug 18)

Drafted By/Date: B. Fisher, MD 10/01/03

Approved By/Date: QM Committee 10/28/03

Revised By/Date: B. Fisher, MD 01/08/06

Approved By/Date: QM Committee 01/24/06

Revised By/Date: B. Fisher, MD 11/13/07

Approved By/Date: QM Committee 12/11/07

Reviewed w/o Revision By/Date: B. Fisher, MD 07/23/09

Approved By/Date: QM Committee 09/08/09

Reviewed without Revision By/Date: M. McNeil, MD 08/11/11

Approved By/Date: QM Committee 09/13/11

Revised By/Date: M. McNeil, MD 08/22/13

Approved By/Date: QM Committee 09/10/13

Revised By/Date: M. McNeil, MD 01/15/16

Approved By/Date: QM Committee 02/16/16

*Consistent with Summary Plan Description (SPD). When there is discordance between this policy and the SPD, the provisions of the SPD prevail.